Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That's some expensive rent. Maybe a few complaints from share holders would make him second guess the instant liquidation.
Good read Dennis, kind of plays into the old theory of starving cancer by limiting refined sugar intake as a homeopathic way of dealing with cancer...
Looks like short interest might be going back up...oh well...big earnings in a week or two.
Rsi has moved positive, macd and mfi have crossed, see if it means anything.
Looks like shorts are still in control, you may have a good opportunity yet...
Likely hard resistance in the 3.93 to 3.96 range...if we reach that another consolidation down to 3.50s probably in order short of any news or earnings release before moving higher. I'm not trading this this one, as with many bio's you never know when they really take off.
Pretty quiet around here lately. Maybe in the the coming days/weeks we'll see some action...looking at charts it would appear mfi rsi macd are all on the rise...hopefully translates into a big move like the last one and I can trim my holdings!!!
Yeah what the hell was I thinking after that big run? I did sell some covered calls at 20 so sort of locked some profits in...
Its behaving like news is imminent...
My 2 cents, with 12% of float short and getting crushed they had to do something...that article was not written in a day, so imo they coordinated a short sell attack and released the article alongside it. Effective for the day...we'll see if it has a lasting effect.
Most of the arguments in his analysis are easily dismissed, and downright misleading. Imo the shorts are frustrated and trying to do whatever it takes to get us priced as a mediocre growth stock.
Forget it, I believe we have very similar positions..
Wow, thanks hype;) Glad we are where we are, but have to trim a few shares here...sold some covered calls when we were at 19 but now trimming a few as this WAS my core position. Any chance you wanta share a few other ideas? NOT going to chance what I had in cryoport in another baby bio related company. May pickup more atrs though...
We are nearing a billion dollar market cap...just cant see how we dont have a major correction before moving much higher. Revs are growing but not fast enough to sustain this valuation.
Is it time to sell a few more covered calls? If earnings don't impress we could get go down big tomorrow!
I quit reading at 'you're right'...as I dont hear that very often;)
On a more serious note, a biotech that is capable of taking on debt and staying afloat is a milestone. It speaks volumes that a lender has seen the books and is willing to double the credit line...they are not in the business to foreclose on companies. Would you rather have an equity raise at a discount to market in hopes of 'someday' being able to secure a loan?
Wow, are you likely better off investing in mutual funds.
Wow, nailed it...how long did your model take to put together?
Hey Hyper, yep still around, and also in cyrx yet...
The way I've been analyzing atrs is off others numbers, seems to be a number very well educated retail investors here. Investor village has a member tracking script numbers weekly and smithonstocks keeps updated his analysis to name a couple.
Your numbers appear very plausible in comparison. The way I see it, the market is very skeptical of atrs, if it was only retail in control I think we would be valued higher. We have a 500m market cap with huge revenue growth likely coming next few quarters, growth bios usually command a huge multiple but we sit at 5x this fiscal year projected revs. Look at cryoport, its not worth 500m imo, but the market thinks so(yes I do hold all my shares yet, but sold nov $20 covered calls last week on a quarter of'em).
Right now, at this time in the market, many stocks are priced too high imo. Atrs however has had little appreciation shown for xyo, which will be telling very soon. The other indicator I like recently is they doubled their credit facility vs doing a secondary. I like to think it shows management is confident in the future rev and bottom line. My 12 month target is 6 to 8 bucks...could be conservative if epi jr and forteo do well.
Same here @3. This SHOULD be low risk right now...we just need good numbers come earnings.
What do you make of this? Are they going to pay off part of that last money raise?
'On June 24, 2019, the Company and Petrichor Opportunities Fund I LP (the “Holder”) agreed to temporarily delay the effectiveness of the mandatory conversion provisions of the Company’s convertible note issued to the Holder (the “Note”), dated as of December 14, 2018, such that in the event the mandatory conversion provisions under Section 3.5 of the Note are triggered prior to July 10, 2019, the Mandatory Conversion Date (as defined in the Note) shall be deemed to occur on July 10, 2019.'
Up after hours again, wonder if news tomorrow...
Moving after years of being idle....is something in the works? Buyout? Management gettin older....maybe another company trying to accumulate shares or someone doing a pump?
Ummm, maybe 'think outside the dewar' would be more appropriate. Plenty to be critical of, as if it doesnt include a dewar they cant seam to do anything. They have huge capabilities with their temp tracking with gps, but havent done anything else with it.
I still think they should look at cold chain food supply as they already have the capability...live alerts when produce gets warm in transit, sits on the doc too long etc etc...much bigger market than bio. Not as sexy but who cares if it makes money!
I'm confident cryoport has no interest in canibis unless some cold logistics is needed as a service they can provide.
I am also confident they are growing revenues significantly with biofarma, and really look forward to their next QR. Being they didn't even pr the bluebird approval/commercial agreement I'd imagine there are other nuggets we're missing out on!
Right on, there IS more than the market is giving atrs credit for. I think the old 'glass is half empty' saying applies here, with the epi and epi jr issues. Then the teva debacle. Much easier to think begative than positive. When that mentality changes and it may need to be backed up by numbers, I think we have a 10 to 20 multiple rev company here. Similar to other small up and coming bios. I see a double up to 4x share price in a year.
Profits are not necessary with small bio's...growth and self sustainability so cash flow positive is the biggy. We'll get there in not too long.
There is no relationship between the 2 companies, it have been made public, you are spreading FALSE information. If anything, it shows how SLOPPY mydx management is with there paperwork...can't even proofread. And its likely they haven't corrected those docs because nobody noticed(or did it on purpose)...maybe you should contact mydx and let them know instead of telling everyone else. Or better yet, maybe I'll contact cryoport and tell them mydx is filing false documents with there company name on them.
Do you by chance USE the marijuana?
Maybe we should be on the nwbo board, however, paranoia saves dollars when something just doesn't feel right. How many years has dvax been in trials? Going on decades? MANY drugs in trials look good all the way through phase 3 then fail. Why keep holding up data if as you say the data is so great where the bar is set so low? If it matches the bar it should get approved.
At least with cyrx we can plainly see progress, and I'm sure more positive surprises to come.
Nwbo is a one trick pony, playing craps...if it hits will be huge, if not kiss your investment goodbye.
Found it on investor village...took a little dip likely due to holiday week.
I still think this is very solid risk/reward ratio given macro picture.
It honestly could be that the form was 'borrowed' from a cyrx filing and they just overlooked the company name change at the bottom.
That is VERY interesting! But I believe it is either a misprint or maybe a fraudulent attempt to get shareholders excited about something that doesn't exist. Please explain how these 2 business can create a synergy together..
Bucciero is not associated with cryoport as far as I can find. In other words, he cannot sign anything as so. And if there WAS such a deal made, Cryoport would need to disclose that publicly as soon as its official.
Well as for cryoport management, I invested WAY too much too early based on they're overly optimistic outlook. I'm not complaining where the stock price is today however I believe its largely the market getting ahead of itself now and based on the paltry revenues right now 600M market cap is hard to swallow...I do understand the market is a future discounter of future values...5 years in advance is hard to believe.
My sell is at 20 even for half my shares.
I may pickup a few more nwbo under .30 as risk to reward is worth the gamble, especially if you think so
Mydx has nothing to do with cryx. And their 10q was awful, and yes I think you are poaching investors of cryoport.
Moderator, can you please delete any posts with mydx in them...thank you.
You mist sit at the $500 blackjack table huh...I cannot see myself putting $100k on nwbo...just too darn many missed deadlines over the years. I only have a tiny holding of 16k shares as a long shot.
Data looks very promising, but management seems lacking.
Anyone see any updated scrip numbers on xyo?
Lotta new blood on this board suddenly. You newcomers sure are upbeat here. Ive been here many years, I hope this is a good sign of things to come...we need more new investors!
So the Bluebird approval wasn't actually PR'd by Cryoport, but this nugget was buried in the 'Nasdaq' closing bell announcement...
"Additionally, Cryoport is now supporting a third commercially approved therapy as bluebird bio's gene therapy Zynteglo™ was recently granted EMA marketing authorization."
So we PR ringing a bell....but NOT supporting another commercial launch???
Novartis selects SAVSU/EVO shippers for ZOLGENSMA. I would assume due to using SAVSU/EVO throughout their trials? Or is SAVSU/EVO a real threat?
https://finance.yahoo.com/news/biolife-solutions-announces-savsu-technologies-120000993.html